Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 6
2006 1
2007 4
2009 1
2010 6
2011 10
2012 10
2013 7
2014 8
2015 4
2016 3
2017 8
2018 12
2019 12
2020 14
2021 14
2022 12
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Müller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, Klein SA, Schubert J, Niederland J, Kaufmann M, Schäfer-Eckart K, Schaich M, Baldauf H, Stölzel F, Petzold C, Röllig C, Alakel N, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Bornhäuser M, Mikesch JH, Schetelig J; Study Alliance Leukemia and the German Cooperative Transplant Study Group. Stelljes M, et al. Among authors: bug g. Lancet Haematol. 2024 May;11(5):e324-e335. doi: 10.1016/S2352-3026(24)00065-6. Epub 2024 Apr 4. Lancet Haematol. 2024. PMID: 38583455 Free article. Clinical Trial.
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies.
Schulz F, Jäger P, Tischer J, Fraccaroli A, Bug G, Hausmann A, Baermann BN, Tressin P, Hoelscher A, Kasprzak A, Nachtkamp K, Schetelig J, Hilgendorf I, Germing U, Dietrich S, Kobbe G. Schulz F, et al. Among authors: bug g. Cancers (Basel). 2024 Jan 26;16(3):532. doi: 10.3390/cancers16030532. Cancers (Basel). 2024. PMID: 38339283 Free PMC article.
Management of Patients Undergoing CAR-T Cell Therapy in Germany.
Penack O, Dreger P, Ajib S, Ayuk F, Baermann BN, Bug G, Kriege O, Jentzsch M, Kobbe G, Koenecke C, Lutz M, Martin S, Schlegel PG, Schroers R, von Tresckow B, Vucinic V, Subklewe M, Bethge W, Wolff D. Penack O, et al. Among authors: bug g. Oncol Res Treat. 2024;47(3):65-75. doi: 10.1159/000536201. Epub 2024 Jan 10. Oncol Res Treat. 2024. PMID: 38198763 Free PMC article.
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease.
Bonig H, Verbeek M, Herhaus P, Braitssch K, Beutel G, Schmid C, Müller N, Bug G, Döring M, von Stackelberg A, Tischer J, Ayuk F, Wulf G, Holtick U, Pfeffermann LM, Jahrsdörfer B, Schrezenmeier H, Kuci S, Kuci Z, Zens A, Tribanek M, Zeiser R, Huenecke S, Bader P. Bonig H, et al. Among authors: bug g. J Transl Med. 2023 Nov 21;21(1):837. doi: 10.1186/s12967-023-04731-1. J Transl Med. 2023. PMID: 37990219 Free PMC article.
Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT.
Saraceni F, Labopin M, Raiola AM, Blaise D, Reményi P, Sorà F, Pavlu J, Bramanti S, Busca A, Berceanu A, Battipaglia G, Visani G, Sociè G, Bug G, Micò C, La Nasa G, Musso M, Olivieri A, Spyridonidis A, Savani B, Ciceri F, Nagler A, Mohty M. Saraceni F, et al. Among authors: bug g. Hemasphere. 2023 Sep 20;7(10):e952. doi: 10.1097/HS9.0000000000000952. eCollection 2023 Oct. Hemasphere. 2023. PMID: 37746158 Free PMC article.
Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party.
Bazarbachi A, Labopin M, Gedde-Dahl T, Remenyi P, Forcade E, Kröger N, Socié G, Craddock C, Bourhis JH, Versluis J, Yakoub-Agha I, Salmenniemi U, El-Cheikh J, Bug G, Esteve J, Nagler A, Ciceri F, Mohty M. Bazarbachi A, et al. Among authors: bug g. Clin Cancer Res. 2023 Nov 1;29(21):4441-4448. doi: 10.1158/1078-0432.CCR-23-0954. Clin Cancer Res. 2023. PMID: 37603683
Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.
Cremer A, Enssle JC, Pfaff S, Kouidri K, Lang F, Brandts C, Zeiher A, Cremer S, Steffen B, Serve H, Bug G. Cremer A, et al. Among authors: bug g. Ann Hematol. 2023 Oct;102(10):2903-2908. doi: 10.1007/s00277-023-05396-y. Epub 2023 Aug 8. Ann Hematol. 2023. PMID: 37552323 Free PMC article. Review.
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial.
Schubert ML, Schmitt A, Hückelhoven-Krauss A, Neuber B, Kunz A, Waldhoff P, Vonficht D, Yousefian S, Jopp-Saile L, Wang L, Korell F, Keib A, Michels B, Haas D, Sauer T, Derigs P, Kulozik A, Kunz J, Pavel P, Laier S, Wuchter P, Schmier J, Bug G, Lang F, Gökbuget N, Casper J, Görner M, Finke J, Neubauer A, Ringhoffer M, Wolleschak D, Brüggemann M, Haas S, Ho AD, Müller-Tidow C, Dreger P, Schmitt M. Schubert ML, et al. Among authors: bug g. J Hematol Oncol. 2023 Jul 22;16(1):79. doi: 10.1186/s13045-023-01470-0. J Hematol Oncol. 2023. PMID: 37481608 Free PMC article.
Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Abou Dalle I, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U, Forcade E, Itäla-Remes M, Dreger P, Bug G, Passweg J, Heuser M, Choi G, Brissot E, Giebel S, Nagler A, Ciceri F, Bazarbachi A, Mohty M. Abou Dalle I, et al. Among authors: bug g. Bone Marrow Transplant. 2023 Jul;58(7):784-790. doi: 10.1038/s41409-023-01961-1. Epub 2023 Apr 11. Bone Marrow Transplant. 2023. PMID: 37041215
126 results